Latest news with #ABIONYXPharma
Yahoo
3 days ago
- Business
- Yahoo
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital
Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) PARIS, June 03, 2025--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (Paris:ABNX) Market: Euronext Paris, Compartment CISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) May 31, 2025 34,931,012 44,381,814 44,086,582 (1) The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended. (2) The total number of net (or "exercisable at a Shareholders' Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the recommendation made by the AMF on 17 July 2007. About ABIONYX Pharma ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines in diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I -based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in sepsis and critical care. View source version on Contacts NewCap Investor relationsLouis-Victor Delouvrierabionyx@ +33 (0)1 44 71 98 53NewCap Media relationsArthur Rouilléabionyx@ +33 (0)1 44 71 00 15 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
28-05-2025
- Business
- Business Wire
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1 st Quarter 2025
TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant apoA-I, today provides an update on its activity and cash position as of March 31, 2025. Selected financial information (IFRS) ABIONYX Pharma recorded consolidated quarterly sales of nearly €1 million in Q1 2025, down on Q1 2024. This decline is cyclical and reflects a wait-and-see attitude on the part of customers in the context of uncertain US customs policy. In the business dedicated to the discovery and development of innovative therapies designed to improve patients' lives, the Company generated no sales in the quarter, as ABIONYX Pharma continues to provide its bioproduct free of charge in the context of compassionate access applications. As at March 31, 2025, the Company had cash and cash equivalents of nearly €4.1 million, before receipt of the estimated €1.08 million Research Tax Credit and after receipt of the first €2.17 million tranche of France 2030 funding. R&D update and anticipated key milestones: Concerning the rare disease known as 'LCAT Deficiency' (Lecithin Cholesterol Acyl-Transferase deficiency or Norum disease), the Company continues to receive new requests for Compassionate Access Authorization (CAA) for recombinant apoA-I, CER-001, from several hospitals around the world. Last May, ABIONYX Pharma sent the European Medicines Agency (EMA) the clinical results of treated patients, with a view to continuing discussions and obtaining feedback for a future application for Compassionate Access. With regard to sepsis, ABIONYX Pharma is pursuing its strategic plan to find a strategic partner for its biomedicine. About ABIONYX Pharma ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines for diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I-based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in Sepsis and critical care.
Yahoo
27-05-2025
- Business
- Yahoo
ABIONYX Pharma Leads The Charge In European Penny Stocks
The European market recently experienced a downturn, with the pan-European STOXX Europe 600 Index ending 0.75% lower after a series of gains, influenced by geopolitical tensions and economic forecasts. In such fluctuating conditions, identifying stocks with strong financial underpinnings becomes crucial for investors seeking stability and growth potential. While the term "penny stock" might seem outdated, these smaller or newer companies can still present significant opportunities when they are supported by robust balance sheets and strategic positioning in their sectors. Name Share Price Market Cap Financial Health Rating Bredband2 i Skandinavien (OM:BRE2) SEK2.31 SEK2.21B ★★★★☆☆ Transferator (NGM:TRAN A) SEK2.14 SEK205.88M ★★★★★☆ Angler Gaming (NGM:ANGL) SEK3.70 SEK277.44M ★★★★★★ Hifab Group (OM:HIFA B) SEK3.38 SEK205.64M ★★★★★★ IMS (WSE:IMS) PLN4.10 PLN138.97M ★★★★☆☆ Cellularline (BIT:CELL) €2.83 €59.69M ★★★★★☆ Netgem (ENXTPA:ALNTG) €0.934 €31.28M ★★★★★★ Euroland Société anonyme (ENXTPA:MLERO) €3.26 €9.49M ★★★★★★ Fondia Oyj (HLSE:FONDIA) €4.80 €17.95M ★★★★★★ Deceuninck (ENXTBR:DECB) €2.145 €296.15M ★★★★★★ Click here to see the full list of 448 stocks from our European Penny Stocks screener. Let's uncover some gems from our specialized screener. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: ABIONYX Pharma SA is a biotech company focused on discovering and developing therapies for renal and ophthalmological diseases, with a market cap of €44.94 million. Operations: The company generates revenue primarily from its Contract Research Organization (CRO) activity, amounting to €4.55 million. Market Cap: €44.94M ABIONYX Pharma, with a market cap of €44.94 million, remains unprofitable and is not expected to achieve profitability in the next three years. Despite generating €4.6 million in revenue from its CRO activities, the company faces challenges with a net loss of €4.4 million for 2024 and an increasing loss trend over five years at 18.6% annually. It has less than one year of cash runway based on current free cash flow and forecasts suggest earnings may decline by an average of 41.1% per year over the next three years, although revenue is projected to grow by 48.32% per year. Click to explore a detailed breakdown of our findings in ABIONYX Pharma's financial health report. Examine ABIONYX Pharma's earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★★★ Overview: KMC Properties ASA currently does not have significant operations and has a market capitalization of NOK70.85 million. Operations: The company generates NOK238 million in revenue from its Industrial and Logistic Properties segment. Market Cap: NOK70.85M KMC Properties ASA, with a market cap of NOK70.85 million, reported NOK238 million in revenue for 2024 but saw a significant drop from the previous year's NOK409 million. The company has recently turned profitable, achieving a net income of NOK864 million compared to a prior net loss. Despite high volatility and an inexperienced board, KMC's debt-free status and outstanding return on equity are notable strengths. Its short-term assets comfortably exceed liabilities, although its share price remains highly volatile. Trading significantly below estimated fair value may present potential opportunities for investors mindful of these dynamics. Click here to discover the nuances of KMC Properties with our detailed analytical financial health report. Examine KMC Properties' past performance report to understand how it has performed in prior years. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Exasol AG develops databases for analytics and data warehousing across Germany, Austria, Switzerland, Great Britain, North America, and internationally with a market cap of €86.40 million. Operations: The company's revenue is primarily generated from the DACH region with €25.97 million, followed by North America at €7.62 million, Great Britain contributing €2.31 million, and the Rest of Europe and Rest of World adding €3.73 million. Market Cap: €86.4M Exasol AG, with a market cap of €86.40 million, has transitioned to profitability, reporting €39.63 million in revenue for 2024 and a net income of €0.23 million compared to a prior loss. The company is debt-free and its short-term assets exceed liabilities, providing financial stability. However, the board's limited experience may be a concern for some investors. Exasol's stock trades significantly below estimated fair value despite stable weekly volatility over the past year and high-quality earnings. Revenue growth is expected in the mid-single-digit range for 2025 as per recent corporate guidance announcements. Dive into the specifics of Exasol here with our thorough balance sheet health report. Evaluate Exasol's prospects by accessing our earnings growth report. Get an in-depth perspective on all 448 European Penny Stocks by using our screener here. Looking For Alternative Opportunities? AI is about to change healthcare. These 22 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:ABNX OB:KMCP and XTRA:EXL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
27-03-2025
- Business
- Yahoo
3 European Penny Stocks With Market Caps Over €30M
As the pan-European STOXX Europe 600 Index has recently edged higher, buoyed by hopes of increased government spending yet tempered by trade tensions, investors are keenly observing opportunities within the market. Penny stocks, a term that may seem outdated but remains relevant in highlighting smaller or less-established companies, can offer significant value when supported by strong financials. By focusing on those with robust balance sheets and potential for growth, investors may uncover promising opportunities among European penny stocks. Name Share Price Market Cap Financial Health Rating Bredband2 i Skandinavien (OM:BRE2) SEK2.01 SEK1.92B ★★★★☆☆ Transferator (NGM:TRAN A) SEK2.52 SEK233.45M ★★★★★☆ Angler Gaming (NGM:ANGL) SEK3.72 SEK278.94M ★★★★★★ Hifab Group (OM:HIFA B) SEK3.88 SEK236.05M ★★★★★★ IMS (WSE:IMS) PLN3.67 PLN124.39M ★★★★☆☆ Cellularline (BIT:CELL) €2.47 €52.01M ★★★★☆☆ Netgem (ENXTPA:ALNTG) €1.00 €33.49M ★★★★★★ High (ENXTPA:HCO) €3.24 €63.64M ★★★★★★ Fondia Oyj (HLSE:FONDIA) €5.00 €18.68M ★★★★★★ Deceuninck (ENXTBR:DECB) €2.19 €302.36M ★★★★★★ Click here to see the full list of 433 stocks from our European Penny Stocks screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: ABIONYX Pharma SA is a biotech company focused on discovering and developing therapies for renal and ophthalmological diseases, with a market cap of €44.59 million. Operations: The company generates revenue of €4.6 million from its research and development activities in innovative medicine development. Market Cap: €44.59M ABIONYX Pharma, a biotech company with a market cap of €44.59 million, operates in the realm of renal and ophthalmological therapies. Despite generating €4.6 million in revenue from innovative medicine development, the company remains unprofitable with increasing losses over the past five years at 18.6% annually. It has sufficient cash runway for more than a year and recently raised additional capital to extend this runway further. While ABIONYX's seasoned management and board offer stability, its negative return on equity (-46.57%) reflects ongoing financial challenges amidst forecasted revenue growth of 42.47% per year. Unlock comprehensive insights into our analysis of ABIONYX Pharma stock in this financial health report. Examine ABIONYX Pharma's earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Lohilo Foods AB (publ) is a Swedish food company with international operations, and it has a market cap of SEK59.89 million. Operations: The company generates revenue primarily from its Own Trademarks at SEK176.55 million and Distributed Trademarks at SEK28.62 million. Market Cap: SEK59.89M Lohilo Foods AB, with a market cap of SEK59.89 million, has shown revenue growth, reporting SEK205.17 million for 2024 compared to SEK182.13 million the previous year. Despite being unprofitable, it reduced its net loss significantly from SEK29.12 million to SEK2.28 million year-on-year and improved its debt-to-equity ratio from 216.3% to 79.8% over five years, though it still holds a high net debt-to-equity ratio of 55.9%. The company maintains a positive free cash flow and has sufficient cash runway for over three years despite not covering short-term liabilities with short-term assets (SEK31.4M vs SEK55.4M). Take a closer look at Lohilo Foods' potential here in our financial health report. Gain insights into Lohilo Foods' past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Transferator AB (publ) is a public private equity and venture capital firm with a market cap of SEK233.45 million. Operations: Transferator generates revenue of SEK55.17 million from its operations in Sweden. Market Cap: SEK233.45M Transferator AB, with a market cap of SEK233.45 million, has demonstrated robust financial health despite recent sales decline to SEK16.41 million in Q4 2024 from SEK21.28 million the previous year. The firm has reduced its debt-to-equity ratio over five years and maintains more cash than total debt, indicating strong liquidity. Its earnings growth of 69.9% last year outpaced the industry average, and it boasts an outstanding return on equity of 74.6%. However, its dividend yield is unsustainable by current earnings and share price volatility remains high compared to peers in Sweden's market. Get an in-depth perspective on Transferator's performance by reading our balance sheet health report here. Evaluate Transferator's historical performance by accessing our past performance report. Gain an insight into the universe of 433 European Penny Stocks by clicking here. Seeking Other Investments? We've found 19 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:ABNX NGM:LOHILO and NGM:TRAN A. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Associated Press
28-02-2025
- Business
- Associated Press
World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances
TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Feb 28, 2025-- ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, today provides an update on its progress and confirms its commitment to the rare disease known as LCAT Deficiency or 'Norum's disease'. About ABIONYX Pharma ABIONYX Pharma is a next-generation biopharma company dedicated to the development of innovative biomedicines for the most severe inflammatory diseases for which there is no effective or existing treatment, even in the rarest indications. The company accelerates the development of breakthrough therapies thanks to in-depth expertise in lipid science and a technological platform based on recombinant apoA-I. ABIONYX Pharma is committed to radically improving the results of sepsis treatments and intensive care. CONTACT: NewCap Investor relations Nicolas Fossiez Louis-Victor Delouvrier [email protected] +33 (0)1 44 71 98 53NewCap Media relations Arthur Rouillé +33 (0)1 44 71 00 15 KEYWORD: MICHIGAN EUROPE UNITED STATES NORTH AMERICA FRANCE SOURCE: ABIONYX Pharma Copyright Business Wire 2025. PUB: 02/28/2025 01:30 AM/DISC: 02/28/2025 01:30 AM
